These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9272403)

  • 1. Moxonidine and cognitive function: interactions with moclobemide and lorazepam.
    Wesnes K; Simpson PM; Jansson B; Grahnén A; Weimann HJ; Küppers H
    Eur J Clin Pharmacol; 1997; 52(5):351-8. PubMed ID: 9272403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects.
    Hanks GW; O'Neill WM; Simpson P; Wesnes K
    Eur J Clin Pharmacol; 1995; 48(6):455-60. PubMed ID: 8582463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo.
    O'Neill WM; Hanks GW; Simpson P; Fallon MT; Jenkins E; Wesnes K
    Pain; 2000 Mar; 85(1-2):209-15. PubMed ID: 10692620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects.
    O'Neill WM; Hanks GW; White L; Simpson P; Wesnes K
    Eur J Clin Pharmacol; 1995; 48(6):447-53. PubMed ID: 8582462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers.
    Satzger W; Engel RR; Ferguson E; Kapfhammer H; Eich FX; Hippius H
    Pharmacopsychiatry; 1990 May; 23 Suppl 3():114-9. PubMed ID: 1974070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.
    Patat A; Perault MC; Vandel B; Ulliac N; Zieleniuk I; Rosenzweig P
    Br J Clin Pharmacol; 1995 Jan; 39(1):31-8. PubMed ID: 7756096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
    Küppers HE; Jäger BA; Luszick JH; Gräve MA; Hughes PR; Kaan EC
    J Hypertens; 1997 Jan; 15(1):93-7. PubMed ID: 9050976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
    Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
    Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of moxonidine in the treatment of hypertension.
    Schachter M; Luszick J; Jäger B; Verboom C; Söhlke E
    Drug Saf; 1998 Sep; 19(3):191-203. PubMed ID: 9747666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study.
    Deplanque D; Machuron F; Waucquier N; Jozefowicz E; Duhem S; Somers S; Colin O; Duhamel A; Bordet R
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):925-932. PubMed ID: 30135030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
    Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
    Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry.
    Saletu B; Grünberger J; Linzmayer L
    Int Clin Psychopharmacol; 1986 Apr; 1(2):145-64. PubMed ID: 2883214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.
    Krystal JH; Karper LP; Bennett A; D'Souza DC; Abi-Dargham A; Morrissey K; Abi-Saab D; Bremner JD; Bowers MB; Suckow RF; Stetson P; Heninger GR; Charney DS
    Psychopharmacology (Berl); 1998 Feb; 135(3):213-29. PubMed ID: 9498724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
    de Haas SL; de Visser SJ; van der Post JP; de Smet M; Schoemaker RC; Rijnbeek B; Cohen AF; Vega JM; Agrawal NG; Goel TV; Simpson RC; Pearson LK; Li S; Hesney M; Murphy MG; van Gerven JM
    J Psychopharmacol; 2007 Jun; 21(4):374-83. PubMed ID: 17092968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.